Select Publications

Baum M et al; ATAC Trialists’ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 2002;359(9324):2131-9. Abstract

Baum M et al; The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists’ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98(9):1802-10. Abstract

Boccardo F et al. Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment. Breast Cancer Res Treat 2003;82(1 Suppl 1):3;Abstract 3.

Bundred NJ et al. Fulvestrant, an estrogen receptor downregulator, reduces cell turnover index more effectively than tamoxifen. Anticancer Res 2002;22(4):2317-9. Abstract

Coleman R et al. Association between prior chemotherapy and the adverse event (AE) profile of adjuvant anastrozole (A) or tamoxifen (T): A retrospective analysis from the ATAC trial. Proc ASCO 2004;Abstract 767.

Distler W et al. Impact of age on the gynecologic adverse event (AE) profile of anastrozole (A) or tamoxifen (T) in the ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) trial. Proc ASCO 2004;Abstract 770.

Dowsett M, on Behalf of the ATAC Trialists Group. Analysis of time to recurrence in the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial according to estrogen receptor and progesterone receptor status. Breast Cancer Res Treat 2003;82(1 Suppl 1):6;Abstract 4.

Dowsett M et al. Molecular changes in tamoxifen-relapsed breast cancer: Relationship between ER, HER2 and P38-MAP-kinase. Proc ASCO 2003;Abstract 7.

Dowsett M et al. Molecular effects of anastrozole (A) and tamoxifen (T) alone and combined (C) in the IMPACT trial of neoadjuvant treatment of primary breast cancer. Proc ASCO 2004; Abstract 537.

Dowsett M, Smith I, on behalf of the IMPACT Trialists. Greater Ki67 response after 2 weeks neoadjuvant treatment with anastrozole (A) than with tamoxifen (T) or anastrozole plus tamoxifen (C) in the IMPACT trial: A potential predictor of relapse-free survival. Breast Cancer Res Treat 2003;82(1 Suppl 1):6;Abstract 2.

Ellis MJ et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB- 1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 2001;19(18):3808-16. Abstract

Forward DP et al. Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br J Cancer 2004;90(3):590-4. Abstract

Gancberg D et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 2002;13(7):1036-43. Abstract

Goss PE et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349(19):1793-802. Abstract

Harper-Wynne CL et al. Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer. J Clin Oncol 2002;20(4):1026-35. Abstract

Johnston S. Fulvestrant and the sequential endocrine cascade for advanced breast cancer. Br J Cancer 2004;90(Suppl 1):15-8. Abstract

Jones SE et al. A retrospective analysis of the proportion of patients responding for > 1 year in two phase III studies of fulvestrant vs. anastrozole. Proc ASCO 2004;Abstract 737.

Reddy JC et al. Patient benefit from trastuzumab plus a taxane regardless of estrogen receptor (ER) status or prior adjuvant therapy for HER2+ metastatic breast cancer (MBC). Proc ASCO 2004;Abstract 674.

Robertson J et al. Oestrogen receptor expression in human breast cancer during long-term fulvestrant treatment. Proc ASCO 2004;Abstract 536.

Robertson JF et al. Pharmacokinetics of a single dose of fulvestrant prolonged-release intramuscular injection in postmenopausal women awaiting surgery for primary breast cancer. Clin Ther 2003;25(5):1440-52. Abstract

Santen RJ et al. Adaptive hypersensitivity to estrogen: Mechanism for sequential responses to hormonal therapy in breast cancer. Clin Cancer Res 2004;10(1 Pt 2):337S-45S. Abstract

Smith I, Dowsett M, on behalf of the IMPACT Trialists. Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive (ER+) operable breast cancer in postmenopausal women: The IMPACT trial. Breast Cancer Res Treat 2003;82(1 Suppl 1):6;Abstract 1.

Smith IE et al. Assessment of lipids and bone-derived resorption products during neoadjuvant therapy with anastrozole (A), v tamoxifen (T), v combination (C) in the IMPACT trial. Proc ASCO 2004;Abstract 675.

Vergote I, Robertson JF. Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: Results from clinical trials. Br J Cancer 2004;90(Suppl 1):11-4. Abstract

Home · Search